Bank Julius Baer & Co’s Aldeyra Therapeutics ALDX Stock Holding History

Bank Julius Baer & Co’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3,500	Closed	-$14K	–	590
2021 Q4	$14K	Hold	3,500	–	–	﹤0.01%	768
2021 Q3	$31K	Sell	3,500 -30	-0.8%	-$275	﹤0.01%	719
2021 Q2	$40K	Buy	3,530 +30	+0.9%	+$361	﹤0.01%	701
2021 Q1	$42K	Buy	3,500 +1,022	+41%	+$11.8K	﹤0.01%	681
2020 Q4	$17K	Sell	2,478 -22	-0.9%	-$154	﹤0.01%	755
2020 Q3	$19K	Buy	+2,500	New	+$16.1K	﹤0.01%	660

Other funds holding ALDX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

TLP

Tri Locum Partners New York $713M AUM 68.92% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Bank Julius Baer & Co's ALDX Position: Q1 2022 in Review

Bank Julius Baer & Co sold out of Aldeyra Therapeutics (ALDX) in Q1 2022, closing a stake of 3,500 shares — an estimated $14K sold.

Bank Julius Baer & Co first reported a position in ALDX in Q3 2020 and held it in 6 quarters. The position peaked at $42K in Q1 2021. 111 funds tracked by Wall St. Rank hold ALDX as of Q1 2022.

Bank Julius Baer & Co reported no remaining Aldeyra Therapeutics position as of Q1 2022 after selling out during the quarter.
Bank Julius Baer & Co sold 3,500 Aldeyra Therapeutics shares in Q1 2022, an estimated $14K.
Bank Julius Baer & Co first reported a position in Aldeyra Therapeutics in Q3 2020 and held it in 6 quarters.
Bank Julius Baer & Co's Aldeyra Therapeutics position peaked at $42K in Q1 2021.
111 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2022.

Based on Bank Julius Baer & Co's 13F filing for Q1 2022, filed 9 May 2022.